Mouse tissue distribution and persistence of the food-born fusariotoxins Enniatin B and Beauvericin

Toxicology Letters

Volumn 247, Issue , 2016, Pages 35-44

  Rodríguez Carrasco, Yelko ^a   Heilos, Daniela ^b,c,d   Richter, Lennart ^f   Süssmuth, Roderich D ^f   Heffeter, Petra ^c,d,e   Sulyok, Michael ^g   Kenner, Lukas ^c,d,h   Berger, Walter ^c,d,e   Dornetshuber Fleiss, Rita ^b,c,d  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e Research Platform Translational Cancer Therapy Research   (Austria)

^f TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

^g UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^h UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Beauvericin; Enniatin B; In vivo; LC MS MS; Metabolism

Indexed keywords

ANTINEOPLASTIC AGENT; BEAUVERICIN; DRUG METABOLITE; ENNIATIN; FAT; FUSARIOTOXIN; MYCOTOXIN; UNCLASSIFIED DRUG; DEPSIPEPTIDE; ENNIATINS; T 2 TOXIN;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY FLUID; COLON; CONTROLLED STUDY; DEMETHYLATION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG METABOLISM; DRUG POTENCY; FOOD CONTAMINATION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SERUM; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; TUMOR VOLUME; URINE; ANIMAL; BIOAVAILABILITY; DRUG EFFECTS; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, LIQUID; COLON; DEPSIPEPTIDES; LIVER; MALE; MICE; T-2 TOXIN; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 84958520908     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2016.02.008     Document Type: Article

References (45)

1. Behm C., Follmann W., Degen G.H. Cytotoxic potency of mycotoxins in cultures of V79 lung fibroblast cells. J. Toxicol. Environ. Health Part A 2012, 75:1226-1231.
2. Blais L.A., Apsimon J.W., Blackwell B.A., Greenhalgh R., Miller J.D. Isolation and characterization of enniatins from fusarium-avenaceum daom-196490. Can. J. Chem. 1992, 70:1281-1287.
3. Chan K.K., Bakhtiar R., Jiang C. Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS. Invest. New Drugs 1997, 15:195-206.
4. Chang C.Y., Ke D.S., Chen J.Y. Essential fatty acids and human brain. Acta Neurol. Taiwan 2009, 18:231-241.
5. Chen B.F., Tsai M.C., Jow G.M. Induction of calcium influx from extracellular fluid by beauvericin in human leukemia cells. Biochem. Biophys. Res. Commun. 2006, 340:134-139.
6. Cooney G.F., Habucky K., Hoppu K. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin. Pharmacokinet. 1997, 32:481-495.
7. Decision, C., 2002. Commission Decision 2002/657/EC implementing Council Directive 96/23/EC concerning the Performance of Analytical Methods and the Interpretation of Results.
8. Devreese M., Broekaert N., De Mil T., Fraeyman S., De Backer P., Croubels S. Pilot toxicokinetic study and absolute oral bioavailability of the Fusarium mycotoxin enniatin B1 in pigs. Food Chem. Toxicol. 2014, 63:161-165.
9. Di L., Kerns E.H., Carter G.T. Drug-like property concepts in pharmaceutical design. Curr. Pharm. Des. 2009, 15:2184-2194.
10. Dornetshuber R., Heffeter P., Kamyar M.R., Peterbauer T., Berger W., Lemmens-Gruber R. Enniatin exerts p53-dependent cytostatic and p53-independent cytotoxic activities against human cancer cells. Chem. Res. Toxicol. 2007, 20:465-473.
11. Dornetshuber R., Heffeter P., Lemmens-Gruber R., Elbling L., Marko D., Micksche M., Berger W. Oxidative stress and DNA interactions are not involved in Enniatin- and Beauvericin-mediated apoptosis induction. Mol. Nutr. Food Res. 2009, 53:1112-1122.
12. Dornetshuber R., Heffeter P., Sulyok M., Schumacher R., Chiba P., Kopp S., Koellensperger G., Micksche M., Lemmens-Gruber R., Berger W. Interactions between ABC-transport proteins and the secondary Fusarium metabolites enniatin and beauvericin. Mol. Nutr. Food Res. 2009, 53:904-920.
13. Dornetshuber-Fleiss R., Heilos D., Mohr T., Richter L., Sussmuth R.D., Zlesak M., Novicky A., Heffeter P., Lemmens-Gruber R., Berger W. The naturally born fusariotoxin Enniatin B and Sorafenib exert synergistic activity against cervical cancer in vitro and in vivo. Biochem. Pharmacol. 2014, 93.
14. Dornetshuber-Fleiss R., Heilos D., Mohr T., Richter L., Sussmuth R.D., Zlesak M., Novicky A., Heffeter P., Lemmens-Gruber R., Berger W. The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo. Biochem. Pharmacol. 2015, 93:318-331.
15. European Commission Health and Consumer Protection directorate-general, 2013. SANCO/12571/2013. Method Validation and Quality Control Procedures for Pesticide Residues Analysis in Food and Feed.
16. Faeste C.K., Ivanova L., Uhlig S. In vitro metabolism of the mycotoxin enniatin B in different species and cytochrome p450 enzyme phenotyping by chemical inhibitors. Drug Metab. Dispos. 2011, 39:1768-1776.
17. Ficheux A.S., Sibiril Y., Parent-Massin D. Effects of beauvericin, enniatin b and moniliformin on human dendritic cells and macrophages: an in vitro study. Toxicon 2013, 71:1-10.
18. Fornelli F., Minervini F., Logrieco A. Cytotoxicity of fungal metabolites to lepidopteran (Spodoptera frugiperda) cell line (SF-9). J. Invertebr. Pathol. 2004, 85:74-79.
19. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
20. Ivanov V.T., Evstratov A.V., Sumskaya L.V., Melnik E.I., Chumburidze T.S., Portnova S.L., Balashova T.A., Ochinnikov Y.A. Sandwich complexes as a functional form of the enniatin ionophores. FEBS Lett. 1973, 36:65-71.
21. Ivanova L., Skjerve E., Eriksen G.S., Uhlig S. Cytotoxicity of enniatins A, A1, B, B1, B2 and B3 from Fusarium avenaceum. Toxicon 2006, 47:868-876.
22. Ivanova L., Faeste C.K., Uhlig S. In vitro phase I metabolism of the depsipeptide enniatin B. Anal. Bioanal. Chem. 2011, 400:2889-2901.
23. Jestoi M., Rokka M., Peltonen K. An integrated sample preparation to determine coccidiostats and emerging Fusarium-mycotoxins in various poultry tissues with LC-MS/MS. Mol. Nutr. Food Res. 2007, 51:625-637.
24. Jestoi M. Emerging fusarium-mycotoxins fusaproliferin, beauvericin, enniatins, and moniliformin: a review. Crit. Rev. Food Sci. Nutr. 2008, 48:21-49.
25. Juan C., Manyes L., Font G., Juan-Garcia A. Evaluation of immunologic effect of Enniatin A and quantitative determination in feces, urine and serum on treated Wistar rats. Toxicon 2014, 87:45-53.
26. Lin H.I., Lee Y.J., Chen B.F., Tsai M.C., Lu J.L., Chou C.J., Jow G.M. Involvement of Bcl-2 family, cytochrome c and caspase 3 in induction of apoptosis by beauvericin in human non-small cell lung cancer cells. Cancer Lett. 2005, 230:248-259.
27. Malachova A., Sulyok M., Beltran E., Berthiller F., Krska R. Optimization and validation of a quantitative liquid chromatography-tandem mass spectrometric method covering 295 bacterial and fungal metabolites including all regulated mycotoxins in four model food matrices. J. Chromatogr. A 2014, 1362:145-156.
28. Manyes L., Escriva L., Serrano A.B., Rodriguez-Carrasco Y., Tolosa J., Meca G., Font G. A preliminary study in Wistar rats with enniatin A contaminated feed. Toxicol. Mech. Methods 2014, 24:179-190.
29. Meca G., Manes J., Font G., Ruiz M.J. Study of the potential toxicity of commercial crispy breads by evaluation of bioaccessibility and bioavailability of minor Fusarium mycotoxins. Food Chem. Toxicol. 2012, 50:288-294.
30. Mei L., Zhang L., Dai R. An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. J. Enzyme Inhib. Med. Chem. 2009, 24:753-762.
31. Nassar A.E., Kamel A.M., Clarimont C. Improving the decision-making process in structural modification of drug candidates: reducing toxicity. Drug Discov. Today 2004, 9:1055-1064.
32. Nassar A.E., Kamel A.M., Clarimont C. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. Drug Discov. Today 2004, 9:1020-1028.
33. Panel E.C. Scientific Opinion on the risks to human and animal health related to the presence of beauvericin and enniatins in food and feed. EFSA J. 2014, 12:3802.
34. Rodriguez-Antona C., Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006, 25:1679-1691.
35. Schlederer M., Mueller K.M., Haybaeck J., Heider S., Huttary N., Rosner M., Hengstschlager M., Moriggl R., Dolznig H., Kenner L. Reliable quantification of protein expression and cellular localization in histological sections. PLoS One 2014, 9:e100822.
36. Sussmuth R., Muller J., von Dohren H., Molnar I. Fungal cyclooligomer depsipeptides: from classical biochemistry to combinatorial biosynthesis. Nat. Prod. Rep. 2011, 28:99-124.
37. Taevernier L., Detroyer S., Veryser L., De Spiegeleer B. Enniatin-containing solutions for oromucosal use: quality-by-design ex-vivo transmucosal risk assessment of composition variability. Int. J. Pharm. 2015, 491:144-151.
38. Taevernier L., Veryser L., Roche N., Peremans K., Burvenich C., Delesalle C., De Spiegeleer B. Human skin permeation of emerging mycotoxins (beauvericin and enniatins). J. Expo. Sci. Environ. Epidemiol. 2015.
39. VanderMolen K.M., McCulloch W., Pearce C.J., Oberlies N.H. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J. Antibiot. (Tokyo) 2011, 64:525-531.
40. Watjen W., Debbab A., Hohlfeld A., Chovolou Y., Kampkotter A., Edrada R.A., Ebel R., Hakiki A., Mosaddak M., Totzke F., Kubbutat M.H., Proksch P. Enniatins A1, B and B1 from an endophytic strain of Fusarium tricinctum induce apoptotic cell death in H4IIE hepatoma cells accompanied by inhibition of ERK phosphorylation. Mol. Nutr. Food Res. 2008, 53:431-440.
41. Watjen W., Debbab A., Hohlfeld A., Chovolou Y., Proksch P. The mycotoxin beauvericin induces apoptotic cell death in H4IIE hepatoma cells accompanied by an inhibition of NF-kappaB-activity and modulation of MAP-kinases. Toxicol. Lett. 2014, 231:9-16.
42. World Health Organization/FAO Evaluation of Certain Mycotoxins in Food 2002, 1-65. JEFCA.
43. Yeh C.T., Rao Y.K., Ye M., Wu W.S., Chang T.C., Wang L.S., Wu C.H., Wu A.T., Tzeng Y.M. Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging. Toxicol. Appl. Pharmacol. 2012, 261:31-41.
44. van Montfoort J.E., Hagenbuch B., Groothuis G.M., Koepsell H., Meier P.J., Meijer D.K. Drug uptake systems in liver and kidney. Curr. Drug Metab. 2003, 4:185-211.
45. Yuca K., Cankaya H., Bayram I., Ozbek H., Kiris M. Local irritant effects of topical oral sprays on oral mucosa in mice. Adv. Ther. 2006, 23:98-106.